Literature DB >> 10882177

Long term survivors of childhood leukemia.

S Shusterman1, A T Meadows.   

Abstract

Changes in therapy, primarily intensification, for childhood leukemias have significantly improved cure rates during the past 30 years. The increasing number of survivors has led to a heightened appreciation of the late complications of treatment caused by both radiation and chemotherapy. Important late effects include decreased growth, poor school performance, altered cardiac function, infertility, and second malignant neoplasms. The long term outcome of children and adolescents suffering from the most recently recognized acute complication of treatment, avascular necrosis of weight-bearing bones, is still not known. These, and all patients treated on clinical trials, should be followed throughout their lives. Many of the complications of treatment are often not realized until years after the completion of therapy; some have been found to be related to dose intensity, emphasizing the importance of clinical trials that examine reduction of therapy for diseases with excellent cure rates. A successful example of this strategy is the elimination or reduction of radiation dose for the prevention of central nervous system acute lymphocytic leukemia. This has resulted in fewer long term central nervous system complications without a decrease in survival rates. As knowledge of late effects increases, design of future trials will need to focus on striking a balance between cure and long term toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882177     DOI: 10.1097/00062752-200007000-00004

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  10 in total

Review 1.  Topics in pediatric leukemia--acute lymphoblastic leukemia and late effects in long-term survivors.

Authors:  Jacqueline Casillas; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-03-07

Review 2.  Titin: physiological function and role in cardiomyopathy and failure.

Authors:  Henk Granzier; Yiming Wu; Labeit Siegfried; Martin LeWinter
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

Review 3.  Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?

Authors:  Saro H Armenian; Smita Bhatia
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

4.  Therapy-Induced Senescence Drives Bone Loss.

Authors:  Zhangting Yao; Bhavna Murali; Qihao Ren; Xianmin Luo; Douglas V Faget; Tom Cole; Biancamaria Ricci; Dinesh Thotala; Joseph Monahan; Jan M van Deursen; Darren Baker; Roberta Faccio; Julie K Schwarz; Sheila A Stewart
Journal:  Cancer Res       Date:  2020-01-13       Impact factor: 12.701

Review 5.  Minimising the long-term adverse effects of childhood leukaemia therapy.

Authors:  Claudia Langebrake; Dirk Reinhardt; Jörg Ritter
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Effects of doxorubicin administration on bone strength and quality in sedentary and physically active Wistar rats.

Authors:  H Fonseca; A Carvalho; J Esteves; V I Esteves; D Moreira-Gonçalves; J A Duarte
Journal:  Osteoporos Int       Date:  2016-06-18       Impact factor: 4.507

7.  Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ.

Authors:  Tapasi Rana; Anwesa Chakrabarti; Michael Freeman; Swati Biswas
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

8.  Doxorubicin Induces Bone Loss by Increasing Autophagy through a Mitochondrial ROS/TRPML1/TFEB Axis in Osteoclasts.

Authors:  Hyun-Jung Park; Sun-Young Yoon; Jung-Nam Park; Jae-Hee Suh; Hye-Seon Choi
Journal:  Antioxidants (Basel)       Date:  2022-07-28

9.  Effect of dexrazoxane and amifostine on the vertebral bone quality of Doxorubicin treated male rats.

Authors:  F Mwale; G Marguier; J A Ouellet; A Petit; L M Epure; J Antoniou; L E Chalifour
Journal:  Open Orthop J       Date:  2008-07-14

Review 10.  Preservation of fertility in females treated for cancer.

Authors:  Yunhai Chuai; Xiaobin Xu; Aiming Wang
Journal:  Int J Biol Sci       Date:  2012-08-01       Impact factor: 6.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.